Document Type: Original Article

Authors

1 Oral and Dental Disease Research Center, School of Dentistry, Shiraz University of Medical Sciences, Shiraz, Iran.

2 Dept. of Pathology, School of Dentistry, Shiraz University of Medical Sciences, Shiraz, Iran.

3 Molecular Dermatology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.

10.30476/dentjods.2020.84667.1096

Abstract

Statement of the Problem: Lichen planus disease is a chronic inflammatory disorder of mucosal and cutaneous tissues, which its etiology and pathogenesis are unclear. Cytokines play an important role in the initiation, maintenance of inflammatory and intercellular cross-talk.
Purpose: We assessed serum levels of IL-22 in patients with oral and cutaneous lichen planus and made comparison with healthy individuals.
Materials and Method: Peripheral blood samples of 40 patients with lichen planus disease, included two groups of oral lichen planus (n=20) and cutaneous lichen planus (n=20) were compared with 32 healthy individuals. Serum samples were prepared from LP patients, using a commercial ELISA Kit, IL-22 concentration was measured in each serum sample. The obtained data were then analyzed using the Kruskal-Wallis one-way analysis of variance.
Results: IL-22 serums level was significantly higher in patients with oral lichen planus than the healthy control group (p< 0.001). No statistically significant differences were observed in serum levels of IL-22 in cutaneous lichen planus patients compared to the controls (p= 0.183).
Conclusion: Increased IL-22 serum levels in patients with oral lichen planus may play an important role in the pathogenesis of oral Lichen planus. The administration of the recombinant or antagonist of IL-22 could be a new therapeutic opportunity in the treatment of oral lichen planus.

Keywords